Advertisement
Sponsored by State University of New York - Upstate Medical University
Phase | Quota | Distance |
---|---|---|
Phase 0 | Near |
The investigators are proposing to test a medication derived from our prior studies of the gene SLC9A9. This one gene makes NHE proteins that control how we learn and remember items, which is impaired in ADHD and may cause an inability to plan, prioritize, self-monitor,inihibit, initiate, self-correct, or control one's behavior. The investigators now propose to investigate the therapeutic utility of an NHE inhibitor, amiloride hydrochloride, for the treatment of attention deficit hyperactivity disorder (ADHD) in medication-naïve adults with ADHD.
Study Start Date: September 2012
Estimated Completion Date: September 2017
Specialties: Pediatrics: Child/Adolescent Psych Psychiatry: Child/Adolescent Psych
Get your trial in front of 1000s of physicians and patients.
Visit ClinicalTrialsLocator.com to find out how you can feature this clinical trial.
Advertisement
Advertisement
Pain Management NP opportunity near Worcester, MA (2767 Worcester, MA - Today |
Branson, Missouri Family Medicine - Mercy - Table Rock Lake, $300k Salary, Beautiful Ozark Mountains Branson, MO - Today |
Family Medicine / Internal Medicine Physician Opportunity in South Georgia Waycross, GA - Today |
Primary Care Opportunity to join Private Practice - Portsmouth, New Hampshire Portsmouth, NH - Today |
Upload Your CV |
Advertisement
Don't Have Account? Sign Up here.
Enter your email address and a password reset email will be sent to you.
or
Verification
Please submit one of the following:
— Action Required —
Your browser is currently blocking ads. We depend on ad sponsorships in order to keep this site free to the healthcare provider community. Help us keep this site free by turning off your ad blocker.
Turn Off Ad Blocker
We have detected that you are currently blocking ads. We kindly ask that you enable ads when visiting our site. We depend on ad sponsorships in order to keep this site free to the healthcare provider community.